These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24598781)

  • 41. Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.
    Gordon CM; Cleveland RH; Baltrusaitis K; Massaro J; D'Agostino RB; Liang MG; Snyder B; Walters M; Li X; Braddock DT; Kleinman ME; Kieran MW; Gordon LB
    Bone; 2019 Aug; 125():103-111. PubMed ID: 31077852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
    Glynn MW; Glover TW
    Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome.
    Davies BS; Yang SH; Farber E; Lee R; Buck SB; Andres DA; Spielmann HP; Agnew BJ; Tamanoi F; Fong LG; Young SG
    J Lipid Res; 2009 Jan; 50(1):126-34. PubMed ID: 18757838
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Embryonic senescence and laminopathies in a progeroid zebrafish model.
    Koshimizu E; Imamura S; Qi J; Toure J; Valdez DM; Carr CE; Hanai J; Kishi S
    PLoS One; 2011 Mar; 6(3):e17688. PubMed ID: 21479207
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lamin A, farnesylation and aging.
    Reddy S; Comai L
    Exp Cell Res; 2012 Jan; 318(1):1-7. PubMed ID: 21871450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment.
    Villa-Bellosta R; Rivera-Torres J; Osorio FG; Acín-Pérez R; Enriquez JA; López-Otín C; Andrés V
    Circulation; 2013 Jun; 127(24):2442-51. PubMed ID: 23690466
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of the Hutchinson-Gilford progeria mutation during osteoblast development results in loss of osteocytes, irregular mineralization, and poor biomechanical properties.
    Schmidt E; Nilsson O; Koskela A; Tuukkanen J; Ohlsson C; Rozell B; Eriksson M
    J Biol Chem; 2012 Sep; 287(40):33512-22. PubMed ID: 22893709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.
    Toth JI; Yang SH; Qiao X; Beigneux AP; Gelb MH; Moulson CL; Miner JH; Young SG; Fong LG
    Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12873-8. PubMed ID: 16129834
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progeria Research Day at Brunel University.
    Bridger JM; Eskiw CH; Makarov EM; Tree D; Kill IR
    Nucleus; 2011; 2(6):517-22. PubMed ID: 22064469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The truncated prelamin A in Hutchinson-Gilford progeria syndrome alters segregation of A-type and B-type lamin homopolymers.
    Delbarre E; Tramier M; Coppey-Moisan M; Gaillard C; Courvalin JC; Buendia B
    Hum Mol Genet; 2006 Apr; 15(7):1113-22. PubMed ID: 16481358
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathological modelling of pigmentation disorders associated with Hutchinson-Gilford Progeria Syndrome (HGPS) revealed an impaired melanogenesis pathway in iPS-derived melanocytes.
    Lo Cicero A; Saidani M; Allouche J; Egesipe AL; Hoch L; Bruge C; Sigaudy S; De Sandre-Giovannoli A; Levy N; Baldeschi C; Nissan X
    Sci Rep; 2018 Jun; 8(1):9112. PubMed ID: 29904107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hutchinson-Gilford progeria mutant lamin A primarily targets human vascular cells as detected by an anti-Lamin A G608G antibody.
    McClintock D; Gordon LB; Djabali K
    Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2154-9. PubMed ID: 16461887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eliminating the synthesis of mature lamin A reduces disease phenotypes in mice carrying a Hutchinson-Gilford progeria syndrome allele.
    Yang SH; Qiao X; Farber E; Chang SY; Fong LG; Young SG
    J Biol Chem; 2008 Mar; 283(11):7094-9. PubMed ID: 18178963
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transient introduction of human telomerase mRNA improves hallmarks of progeria cells.
    Li Y; Zhou G; Bruno IG; Zhang N; Sho S; Tedone E; Lai TP; Cooke JP; Shay JW
    Aging Cell; 2019 Aug; 18(4):e12979. PubMed ID: 31152494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A lamin A protein isoform overexpressed in Hutchinson-Gilford progeria syndrome interferes with mitosis in progeria and normal cells.
    Cao K; Capell BC; Erdos MR; Djabali K; Collins FS
    Proc Natl Acad Sci U S A; 2007 Mar; 104(12):4949-54. PubMed ID: 17360355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lamin A precursor induces barrier-to-autointegration factor nuclear localization.
    Capanni C; Cenni V; Haraguchi T; Squarzoni S; Schüchner S; Ogris E; Novelli G; Maraldi N; Lattanzi G
    Cell Cycle; 2010 Jul; 9(13):2600-10. PubMed ID: 20581439
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review.
    Arancio W; Pizzolanti G; Genovese SI; Pitrone M; Giordano C
    Gerontology; 2014; 60(3):197-203. PubMed ID: 24603298
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progeria, the nucleolus and farnesyltransferase inhibitors.
    Mehta IS; Bridger JM; Kill IR
    Biochem Soc Trans; 2010 Feb; 38(Pt 1):287-91. PubMed ID: 20074076
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The posttranslational processing of prelamin A and disease.
    Davies BS; Fong LG; Yang SH; Coffinier C; Young SG
    Annu Rev Genomics Hum Genet; 2009; 10():153-74. PubMed ID: 19453251
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition.
    Marji J; O'Donoghue SI; McClintock D; Satagopam VP; Schneider R; Ratner D; Worman HJ; Gordon LB; Djabali K
    PLoS One; 2010 Jun; 5(6):e11132. PubMed ID: 20559568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.